Jaguar HealthNASDAQ: JAGX

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS SAN FRANCISCO, CA / ACCESSWIRE / November 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaking abstract about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial, which indicates that crofelemer achieved significant results in this subgroup, has been accepted for a poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS). Patients with breast cancer accounted for the majority of participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Severe mucositis/pharyngitis occurred in 70% of head and neck cancer patients in third-party study SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") has initiated the commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the U.S. "Cancer is chaotic, because patients feel a loss of control - over their life, their treatment, and their supportive care needs," said Catherine Collis, Jaguar's Senior Vice President of Growth Strategy. "Jaguar's mission is to change patients' lives for the better, especially in the area of supportive care for complex disease states like cancer.

SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the OnTarget phase 3 study recently conducted by Jaguar family company Napo Pharmaceuticals, was submitted by the study's primary investigators to a relevant oncology conference for consideration for a presentation. In this study 142 patients with solid tumors received placebo tablets and nearly 75 of them were patients with breast cancer receiving targeted therapies with or without standard chemotherapy.

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the company's Phase 3 OnTarget trial indicate that crofelemer achieved statistical significance in this subgroup. Patients with breast cancer accounted for nearly 180 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Jaguar family company Napo Pharmaceuticals for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.

SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on September 19, 2024 at the MedInvest Biotech & Pharma Investor Conference and participate in one-on-one meetings at the event, which is taking place September 18-19 in New York City. Participation Instructions for Jaguar Health's Presentation at the MedInvest Biotech & Pharma Investor Conference When: Thursday, September 19, 2024 from 9:55 AM Eastern to 10:10 AM Eastern Registration link for presentation: Click Here About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain.

Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Service Dog Month, a time devoted to raising awareness and showing appreciation for the extraordinary work service dogs do every day for the people in their care. "September is National Service Dog Month.

The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA discussion; Jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase 3 results Jaguar planning to begin commercial launch in October 2024 for Gelclair ®, the company's third prescription product Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure REMINDER: Jaguar to host investor webcast Tuesday, August 13th at 8:30 a.m. Eastern regarding Q2 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2024 financial results and provided Company updates.

Dr. Elisabetsky is also an advisor to Magdalena Biosciences , the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions As announced , Jaguar recently executed an out-license deal with Magdalena Biosciences for a botanical drug candidate for possible schizophrenia and psychoses indications and for development with potential corporate partners; the global schizophrenia treatment market valued at $8.29 billion SAN FRANCISCO, CA / ACCESSWIRE / August 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Elaine Elisabetsky, PhD, is conducting a talk on Friday, August 2, 2024 from 12:30 PM - 2:00 PM Central covering several decades of research on plant-based medicines used to manage schizophrenia. Dr. Elisabetsky's talk is part of the annual Norman R.

It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, showed a benefit in patients with chronic refractory diarrhea and have been accepted for poster presentations at the American College of Gastroenterology Annual Scientific Meeting, which takes place October 25-30, 2024 at the Pennsylvania Convention Center in Philadelphia. "We are very excited that crofelemer continues to demonstrate clinical robustness in responder analysis trials for multiple gastroenterological conditions - including functional diarrhea and chronic idiopathic diarrhea.